-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, Maiwei Bio-targeting CD47 and PD-L1 dual antibody 6MW3211 was approved for clinical trials, and clinical trials for advanced malignant tumors will soon be launched
In recent years, CD47 monoclonal antibody has become one of the most popular targets
CD47 target-"Don't eat me"
CD47 is a widely expressed transmembrane glycoprotein that binds to the N-terminus of macrophage surface signal regulatory protein α (SIRPα) and sends out a "Don't eat me" signal to inhibit macrophages Phagocytosis
Although the anti-cancer principles of CD47 and SIRPα pathways are very simple, since CD47 is also expressed on the surface of normal cells (especially red blood cells), the off-target toxicity (On target, Off tumor) of CD47 antibodies is always a hidden danger
Optimization of CD47 drugs
In response to the serious blood toxicity problem caused by CD47, relevant companies have begun to explore ways to improve
(1) Improved administration method: Forty Seven's Magrolimab is a representative drug of CD47, and its method of avoiding hematological toxicity is low-dose induction
The efficacy of Magrolimab alone is not optimistic, but the combined effect is excellent
(2) Reduce the ability of the drug to bind to red blood cells
TTI-621 is an IgG1 Fc, and TTI-622 is an IgG4 Fc
(3) Binding to unique epitopes
At the 2020 SITC conference, Tianjing Biological announced the latest clinical progress of TJC4
In addition to the above methods, the special structure of bispecific antibodies is expected to further reduce the off-target toxicity of drugs
summary
Many investors believe that since CD47 is expressed in almost all cancers, it has the same development potential as PD-1 and has a broad market in the future
.
Throughout the world, CD47 has attracted a large number of pharmaceutical companies competing layout, including Forty Seven, Trillium Therapeutics, Hengrui Medicine, Cinda biological, and other appropriate Ming Angke
.
Judging from the current development of CD47, the adverse events of blood toxicity have gradually been broken through, and the excellent data of the combination scheme makes this target worth looking forward to
.
It is hoped that domestic pharmaceutical companies will continue their efforts and bring CD47-related drugs to the market as soon as possible
.
